KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

BusinesswireNov 12 06:30 ET

Needham Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Cuts Target Price to $28

Moomoo NewsNov 4 17:31 ET · Ratings

KalVista Pharmaceuticals: Strategic Financing and Market Potential Drive Buy Rating

TipRanksNov 4 16:35 ET · Ratings

Sector Update: Health Care Stocks Retreat Late Afternoon

MT NewswiresNov 4 15:52 ET

DRI Healthcare Trust Acquires Royalty Stake in Global Sales of Sebetralstat

MT NewswiresNov 4 08:28 ET

KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million

BusinesswireNov 4 07:05 ET